{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:05:44Z","timestamp":1786118744963,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacl.2026.04.015","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:28:13Z","timestamp":1776468493000},"page":"1301-1311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lipid and anti-inflammatory effects of bempedoic acid across treatment regimens: A harmonized meta-analysis of randomized trials"],"prefix":"10.1016","volume":"20","author":[{"given":"Hadeel","family":"Al\u00a0Kayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5724-3572","authenticated-orcid":false,"given":"Rahul","family":"Rajesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadil","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishab","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1115-4610","authenticated-orcid":false,"given":"Bassel","family":"Alrabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.04.015_bib1","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1007\/s11427-025-2948-y","article-title":"Global burden of atherosclerotic cardiovascular disease attributed to lifestyle and metabolic risks","volume":"68","author":"Xu","year":"2025","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.jacl.2026.04.015_bib2","article-title":"From glucose to global burden: three decades of atherosclerotic cardiovascular disease attributable to high fasting plasma glucose and projections to 2040","volume":"36","author":"Yang","year":"2026","journal-title":"Nutr\u00a0Metab\u00a0Cardiovasc\u00a0Dis"},{"key":"10.1016\/j.jacl.2026.04.015_bib3","article-title":"A significant presence in atherosclerotic cardiovascular disease: remnant cholesterol: a review","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.jacl.2026.04.015_bib4","article-title":"Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease","volume":"2020","author":"Patel","year":"2020","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.jacl.2026.04.015_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100701","article-title":"Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond","volume":"19","author":"Safarova","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.04.015_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2025.06.002","article-title":"LDL cholesterol management simplified in adults\u2014lower for longer is better: guidance from the National Lipid Association","author":"Jackson","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.04.015_bib7","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.9248","article-title":"Therapeutic management of dyslipidemia patients at very high cardiovascular risk (CARDIO TRACK): protocol for the observational registry study","volume":"7","author":"Naidoo","year":"2018","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.jacl.2026.04.015_bib8","article-title":"Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis","volume":"9","author":"Cai","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2026.04.015_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2017.05.018","article-title":"Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary care","volume":"263","author":"Guglielmi","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.04.015_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/clc.23935","article-title":"Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease","volume":"46","author":"Desai","year":"2023","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacl.2026.04.015_bib11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/2047487315602861","article-title":"Statin tolerability: in defence of placebo-controlled trials","volume":"23","author":"Tobert","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.04.015_bib12","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.amjcard.2014.02.033","article-title":"Statin intolerance","volume":"113","author":"Ahmad","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2026.04.015_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacl.2026.04.015_bib14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2026.04.015_bib15","article-title":"Triple versus dual lipid-lowering therapy in acute coronary syndrome: the ES-BempeDACS randomized clinical trial","author":"Raposeiras Roub\u00edn","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.04.015_bib16","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1253\/circj.CJ-25-0089","article-title":"Efficacy and safety of bempedoic acid in Japanese patients with hypercholesterolemia\u2014a randomized, double-blind, placebo-controlled phase 3 study (the CLEAR-J Trial)","volume":"89","author":"Yamashita","year":"2025","journal-title":"Circ J"},{"key":"10.1016\/j.jacl.2026.04.015_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2026.04.015_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2021.100278","article-title":"Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins","volume":"8","author":"Bays","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.04.015_bib19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jacl.2021.05.002","article-title":"Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: a randomized, controlled trial","volume":"15","author":"Rubino","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.04.015_bib20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.04.015_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2026.04.015_bib22","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.04.015_bib23","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacl.2019.05.003","article-title":"Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial","volume":"13","author":"Lalwani","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.04.015_bib24","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2026.04.015_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a\u00a0randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.04.015_bib26","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.amjcard.2016.03.043","article-title":"Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy","volume":"117","author":"Ballantyne","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2026.04.015_bib27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.04.015_bib28","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.04.015_bib29","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.04.015_bib30","first-page":"1033","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"key":"10.1016\/j.jacl.2026.04.015_bib31","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.04.015_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.04.015_bib33","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.04.015_bib34","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/07853890.2022.2059559","article-title":"Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis","volume":"54","author":"Tummala","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.jacl.2026.04.015_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1028355","article-title":"Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome","volume":"9","author":"Biolo","year":"2022","journal-title":"Front Cardiovasc Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742600111X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742600111X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:29:02Z","timestamp":1786033742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193328742600111X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S193328742600111X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.04.015","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid and anti-inflammatory effects of bempedoic acid across treatment regimens: A harmonized meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}